Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis Clinical research trials and Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis. Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis clinical trial. Participants frequently get the best healthcare available for their Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.

Home > "I" Clinical Trials Conditions > Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis

Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis



Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis

For Condition: Aspergillosis
Status: Recruiting
Sponsor(s): Sponsor Name Pending ,
Synopsis: Invasive aspergillosis is a type of fungal infection typically identified in very sick patients (for example, patients with cancer or who have had a bone marrow or organ transplant). This study will seek to enroll patients (16 years of age or older) with invasive aspergillosis infections (involving organs or deep tissues) who are failing or could not tolerate standard antifungal therapy. Your doctor will make this determination based upon specific study criteria. Patients that fulfill all study criteria will be treated daily with both the investigational drug and another antifungal agent. The choice of the other agent is up to your doctor. This investigational drug is approved for the treatment of invasive aspergillosis by itself. The safety and efficacy of this investigational drug, in combination with other agents is not known.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: - Patients must meet a specific definition of probable or definite invasive aspergillosis and be considered to have failed or be intolerant of standard antifungal therapy. - The patient must be at least 16 years old and if a woman of childbearing potential, must have a negative serum or urine pregnancy test sensitive to 25 IU hCG prior to enrollment.
Total Enrollment: 

Location and Contact Information:

Call for Information *Recruiting*
Ft. Sam Houston,  Texas,  78234-6200
United States
Recruiting  

Call for Information *Recruiting*
Birmingham,  Alabama,  35294
United States
Recruiting  

Call for Information *Recruiting*
Rochester,  New York,  14642
United States
Recruiting  

Call for Information *Recruiting*
Maywood,  Illinois,  60153
United States
Recruiting  

Call for Information *Recruiting*
Charlottesville,  Virginia,  22908
United States
Recruiting  

Call for Information *Recruiting*
Detroit,  Michigan,  48201
United States
Recruiting  

Call for Information *Recruiting*
Minneapolis,  Minnesota,  55455
United States
Recruiting  

Call for Information *Recruiting*
Buffalo,  New York,  14263
United States
Recruiting  

Call for Information *Recruiting*
Tucson,  Arizona,  85724
United States
Recruiting  

Call for Information *Recruiting*
Boston,  Massachusetts,  02115
United States
Recruiting  

Call for Information *Recruiting*
Augusta,  Georgia,  30912-3125
United States
Recruiting  

Call for Information *Recruiting*
Minneapolis,  Minnesota,  55417
United States
Recruiting  

Call for Information *Recruiting*
Houston,  Texas,  77030-4095
United States
Recruiting  

Call for Information *Recruiting*
Salt Lake City,  Utah,  84132
United States
Recruiting  


Additional Information:
Study ID Numbers:
  0121FI; 
Study Start Date: 
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00076869

Other Aspergillosis Studies:
1. A Safety & Effectiveness Study of Intravenous Anidulafungin with AmBisomeĀ® for Treatment of Invasive Aspergillosis (IA).

2. Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis

3. Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis

4. Voriconazole to Prevent Systemic Fungal Infections in Children

5. A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma

Related Studies:

Other Aspergillosis Clinical Trials
Other Utah Clinical Trials
Other Salt Lake City Clinical Trials

Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis

Modify your Search

  Other Aspergillosis Clinical Trials
  Other Utah Clinical Trials
  Other Salt Lake City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103